Cargando…

In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies

Genome-wide CRISPR screens have been extremely useful in identifying therapeutic targets in diverse cancers by defining genes that are essential for malignant growth. However, most CRISPR screens were performed in vitro and thus cannot identify genes that are essential for interactions with the micr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mercier, Francois E., Shi, Jiantao, Sykes, David B., Oki, Toshihiko, Jankovic, Maja, Man, Cheuk Him, Kfoury, Youmna S., Miller, Elizabeth, He, Shutao, Zhu, Alexander, Vasic, Radovan, Doench, John, Orthwein, Alexandre, Michor, Franziska, Scadden, David T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631646/ https://www.ncbi.nlm.nih.gov/pubmed/35793392 http://dx.doi.org/10.1182/bloodadvances.2022007250

Ejemplares similares

The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression
por: Kfoury, Youmna S., et al.
Publicado: (2023)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma
por: Findlay, Steven, et al.
Publicado: (2023)

Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs
por: Jutzi, Jonas S., et al.
Publicado: (2022)

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?
por: Brunner, Andrew M., et al.
Publicado: (2022)

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
por: Irani, Yazad D., et al.
Publicado: (2023)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

MYB insufficiency disrupts proteostasis in hematopoietic stem cells, leading to age-related neoplasia
por: Clarke, Mary L., et al.
Publicado: (2023)

FOXP1 regulates oxidative stress, SIRT1 expression, and resistance to chemotherapies in acute myeloid leukemia cells
por: Levavasseur, Francoise, et al.
Publicado: (2023)

Impact of preexisting autoimmune disease on myelodysplastic syndromes outcomes: a population analysis
por: Adrianzen-Herrera, Diego, et al.
Publicado: (2023)

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia
por: Matthews, Andrew H., et al.
Publicado: (2022)

Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum
por: Calvo, Xavier, et al.
Publicado: (2022)

Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
por: Balasundaram, Nithya, et al.
Publicado: (2022)

Therapeutic targeting of PRAME with (mTCR)CAR T cells in acute myeloid leukemia
por: Kirkey, Danielle C., et al.
Publicado: (2022)

Optical genome mapping in acute myeloid leukemia: a multicenter evaluation
por: Levy, Brynn, et al.
Publicado: (2022)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

A clinical laboratory–developed LSC17 stemness score assay for rapid risk assessment of patients with acute myeloid leukemia
por: Ng, Stanley W. K., et al.
Publicado: (2022)

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
por: Tahir, Stephen K., et al.
Publicado: (2023)

Genomic landscape of TP53-mutated myeloid malignancies
por: Abel, Haley J., et al.
Publicado: (2023)

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study
por: Stojkov, Igor, et al.
Publicado: (2023)

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2023)

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
por: de Botton, Stéphane, et al.
Publicado: (2023)

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia
por: Lewis, Alexander C., et al.
Publicado: (2022)

Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
por: McCarter, Joseph G. W., et al.
Publicado: (2023)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
por: Bataller, Alex, et al.
Publicado: (2022)

The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
por: Lafage-Pochitaloff, Marina, et al.
Publicado: (2022)

A global study for acute myeloid leukemia with RARG rearrangement
por: Zhu, Hong-Hu, et al.
Publicado: (2023)

Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
por: Homan, Claire C., et al.
Publicado: (2023)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
por: Wakita, Satoshi, et al.
Publicado: (2022)

Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression
por: Stratmann, Svea, et al.
Publicado: (2022)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes
por: Wang, Yu-Hung, et al.
Publicado: (2021)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

CAMK2G is identified as a novel therapeutic target for myelofibrosis
por: Miyauchi, Masashi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uqfcads40sk9lmj2mrlv44mufo